GOSS

Business Context and Reporting Period

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary hypertension (PH). This Form 10-Q covers the quarterly period ended March 31, 2026. The Company operates as a single segment, deriving all revenue from its collaboration with Chiesi Farmaceutici S.p.A. Management has raised substantial doubt about the Company's ability to continue as a going concern, estimating current cash resources will fund operations only into the first quarter of 2027.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $7.1 million (71%) to $17.0 million, driven by higher cost-sharing payments and R&D service performance under the Chiesi Collaboration Agreement.
• Expense Increases:
  • R&D Expenses: Rose $5.0 million to $43.1 million, primarily due to increased clinical trial costs for seralutinib and costs related to the Respira Therapeutics option.
  • G&A Expenses: Surged $10.1 million to $18.7 million. This increase was driven by a $4.6 million severance charge from a workforce reduction, a $2.2 million increase in stock-based compensation (including a $2.9 million incremental cost from stock option repricing), and higher professional fees.
• Workforce Reduction: On March 16, 2026, the Company initiated a reduction of 73 employees (approx. 46% of the workforce) to reduce operating expenses, with estimated charges of $6.1 million recognized in Q1 2026.
• Investing Activities: Net cash provided by investing activities improved to $41.6 million (from $22.1 million) due to significant maturities of marketable securities ($66.6 million) offset by new purchases ($25.0 million).

Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that existing cash is insufficient to fund operations for at least one year. The Company may be forced to curtail operations or seek additional financing, which may not be available on favorable terms.
• Clinical Development:
  • PAH (PROSERA Study): Topline results announced in February 2026 showed a placebo-adjusted improvement in the primary endpoint but missed the prespecified alpha threshold. The Company expects to submit a New Drug Application (NDA) to the FDA in September 2026 pending regulatory dialogue.
  • PH-ILD (SERANATA Study): Enrollment was paused in February 2026 to support resource allocation and evaluate PROSERA implications. Development is expected to resume when feasible.
• Stock Option Repricing: On March 19, 2026, the Board repriced 48.7 million outstanding stock options to an exercise price of $0.45 per share, resulting in $2.9 million of incremental compensation expense.
• Legal Proceedings: A putative class action lawsuit (Kinnamon vs. Gossamer Bio, Inc.) was filed on March 31, 2026, alleging false/misleading statements regarding the Company's business and prospects. The case is currently stayed pending the appointment of lead counsel.
• Debt Obligations: The Company has $200 million in 5.00% Convertible Senior Notes due June 2027. The fair value of these notes was $78.5 million as of March 31, 2026.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for securing additional capital given the "substantial doubt" disclosure and the projection of funding only into Q1 2027.
• Regulatory Path: Monitor the outcome of FDA interactions regarding the PROSERA study results and the timeline for the anticipated September 2026 NDA submission.
• Cost Reduction Efficacy: Assess whether the 46% workforce reduction and associated $6.1 million charge will sufficiently lower the burn rate to extend the cash runway.
• Chiesi Collaboration: Review the stability of the Chiesi partnership, which accounts for 100% of revenue, and the potential impact of the paused PH-ILD study on future cost-sharing payments.
• Legal Exposure: Track the status of the Kinnamon class action lawsuit and potential settlement costs or diversion of management resources.